Intuitive surgical EVP Mark Brosius sells $17,140 in stock By Investing.com

Mark Brosius, Executive Vice President and Chief Manufacturing and Supply Chain Officer at Intuitive Surgical Inc. (), sold company stock totaling $17,140 across two separate transactions last week.

The sales occurred on September 10, 2026, and September 11, 2026. Brosius disposed of 23 shares at a price of $347.66 per share and 25 shares at $365.79 per share, with prices ranging from $347.66 to $365.79. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan, which is set to expire on February 14, 2027.

Following these transactions, Brosius directly holds 764 shares of Intuitive Surgical common stock.The stock currently trades at $369.15, down 34.8% year-to-date despite the company’s strong fundamentals. According to InvestingPro analysis, ISRG appears undervalued based on its Fair Value assessment, placing it among opportunities on the Most Undervalued stocks list. Investors seeking deeper insights can access comprehensive Pro Research Reports and over a dozen additional ProTips for ISRG on InvestingPro.

In other recent news, Intuitive Surgical reported second-quarter sales that increased by 19% to $2.89 billion, surpassing estimates by 2.5%. The company saw a rise in various segments, with instruments and accessories sales up 18% to $1.73 billion, systems sales climbing 19% to $685 million, and services sales growing 21% to $472 million. Earnings per share rose by 28% to $2.80, exceeding analyst expectations by 12%. Following these developments, several analyst firms have adjusted their ratings and price targets for Intuitive Surgical. Oppenheimer upgraded the stock to Outperform, setting a price target of $500, citing a reassessment of risk-reward factors. UBS also initiated coverage with a buy rating and a similar price target of $500, noting the company’s leadership in medical technology. Meanwhile, Bernstein maintained an Outperform rating but lowered its price target to $685 due to U.S. growth concerns. Piper Sandler reiterated an overweight rating with a $470 price target, maintaining a positive outlook on the company.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.